Genmab Ovarian Cancer Drug Rina-S Shows 45.9% Response Rate in Phase 2 Trial

Key Facts

1Genmab announced that Rina-S achieved a confirmed objective response rate of 45.9% in patients with platinum-resistant ovarian cancer.

2Results showed a median duration of response of 12.1 months, with 51% of responders remaining in response at one year.

Genmab announced that its investigational drug Rina-S achieved a confirmed objective response rate of 45.9% in patients with platinum-resistant ovarian cancer. According to a company statement released via GlobeNewswire, the results demonstrated a median duration of response of 12.1 months, with 51% of responders maintaining their response at the one-year mark.

GMAB closed at $34.75 on October 2, 2026, prior to the release of the RAINFOL-01 trial data presented at the IGCS Congress 2026. The clinical program for Rina-S is now expanding to include four Phase 3 trials targeting various indications, including recurrent endometrial cancer and platinum-sensitive ovarian cancer maintenance therapy.